Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10301-10307

  Wang, Di ^a   Guo, Xiao Zhong ^a   Li, Hong Yu ^a   Zhao, Jia Jun ^a   Shao, Xiao Dong ^a   Wu, Chun Yan ^a  

^a Beifang Hospital of Shenyang   (China)

Author keywords

Cyclooxygenase 2; Meta analysis; Pancreatic cancer; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

BIOSYNTHESIS; CARCINOMA; ENZYMOLOGY; HUMAN; META ANALYSIS; MORTALITY; PANCREAS TUMOR; PROGNOSIS;

CARCINOMA; CYCLOOXYGENASE 2; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922391422     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2260-y     Document Type: Article

References (35)

1. Ilic M, Vlajinac H, Marinkovic J, Kocev N. Pancreatic cancer mortality in Serbia from 1991-2010-a joinpoint analysis. Croat Med J. 2013;54(4):369-75.
2. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta. 2011;1815(1):44-64.
3. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis. 2010;28(2):355-8.
4. Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP. 2010;11(3):203-12.
5. Pandol S, Gukovskaya A, Edderkaoui M, Dawson D, Eibl G, Lugea A. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol. 2012;27 Suppl 2:127-34.
6. Reid-Lombardo KM, Fridley BL, Bamlet WR, Cunningham JM, Sarr MG, Petersen GM. Inflammation-related gene variants as risk factors for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1251-4.
7. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33-40.
8. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15(14):4674-9.
9. Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res. 2012;18(18):5031-42.
10. Zhang H, Xu Y, Zhang Z, Liu R,Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.
11. Ozhan G, Lochan R, Leathart JB, Charnley R, Daly AK. Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Pancreas. 2011;40(8):1289-94.
12. Wang R,WangX, Lin F, Gao P,DongK, Zhang HZ. shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem. 2008;317(1-2):179-88.
13. Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues-is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med. 2009;13(9B):3753-63.
14. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets. 2011;12(7):1082-93.
15. Lau MT, Wong AS, Leung PC. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology. 2010;151(7):2985-93.
16. Gangwar R, Mandhani A, Mittal RD. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery. 2011;149(1):126-34.
17. Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, et al. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther. 2012;11(10):2127-37.
18. Sharma SD, Meeran SM, Katiyar SK. Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors. Mol Cancer Ther. 2010;9(3):569-80.
19. Matsubayashi H, Infante JR,Winter J, Klein AP, Schulick R, Hruban R, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6(10):1569-75.
20. Hillion J, Smail SS, Di Cello F, BeltonA, Shah SN, Huso T, et al. The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology. 2012;12(4):372-9.
21. DingW, DH L. E-calcium adherin and cyclooxygenase-2 expression in cancer of pancreas and its clinical significance. Chin J Gen Surg. 2007;16(05):497-500.
22. GuoMM, Liu JW, Jia FX, Xu YH. Expression of survivin and COX- 2 and prognosis of pancreatic cancer patients. Prog Mod Biomed. 2013;13(19):3632-6.
23. Schmid SJ, GlatzelMC,Welke C, KornmannM, Kleger A, Barth TF, et al. Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma. Pancreas. 2013;42(7):1114-9.
24. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmeta-analyses. Eur J Epidemiol. 2010;25(9):603-5.
25. Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672-3.
26. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123-37.
27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in metaanalysis. JAMA. 2006;295(6):676-80.
28. Gao F, Feng YZ, Deng HZ, Li F. The expression of COX-2 in pancreatic carcinoma and its clinical significance. Suzhou Univ J Med Sci. 2005;25(03):466-8.
29. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 2006;59(4):382-6.
30. Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther. 2005;4(12):1943-51.
31. Hermanova M, Trna J, Nenutil R, Dite P, Kala Z. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol. 2008;20(8):732-9.
32. Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009;136(5):1659-68.
33. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001;298(3): 976-85.
34. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, et al. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas. 2008;36(4):385-93.
35. Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol. 2009;9(6):701-15.